Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 5/20 | 0.39 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13930534 | 1.00 | ADORA1 (0.39) | ADORA1SLC29A1ADORA3ADORA2AADORA2B | |
| SCHEMBL13930529 | 0.88 | SLC29A1 (0.52) | ADORA1SLC29A1ADORA3ADORA2AADORA2B | |
| SCHEMBL13375827 | 0.88 | SLC29A1 (0.52) | ADORA1SLC29A1ADORA3ADORA2AADORA2B | |
| SCHEMBL13930566 | 0.88 | SLC29A1 (0.52) | ADORA1SLC29A1ADORA3ADORA2AADORA2B | |
| SCHEMBL16257643 | 0.87 | SLC29A1 (0.41) | ADORA1SLC29A1ADORA3ADORA2AADORA2B | |
| SCHEMBL13213618 | 0.87 | SLC29A1 (0.41) | ADORA1SLC29A1ADORA3ADORA2AADORA2B | |
| SCHEMBL16568376 | 0.85 | POLB (0.48) | ADORA1SLC29A1POLB | |
| SCHEMBL767269 | 0.85 | POLB (0.48) | ADORA1SLC29A1POLB | |
| SCHEMBL13375773 | 0.82 | ADORA1 (0.44) | ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL13375820 | 0.81 | ADORA3 (0.39) | ADORA1SLC29A1ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288516-B2 | Functional molecule, functional molecule synthesizing amidite and target substance analysis method | FUJITSU LIMITED (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20100197902-A1 | NUCLEIC ACID SYNTHESIZING DIMER AMIDITE AND NUCLEIC ACID SYNTHESIZING METHOD | FUJITSU LIMITED (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20100197902-A1 | NUCLEIC ACID SYNTHESIZING DIMER AMIDITE AND NUCLEIC ACID SYNTHESIZING METHOD | FUJITSU LIMITED (JP) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197902-A1 | NUCLEIC ACID SYNTHESIZING DIMER AMIDITE AND NUCLEIC ACID SYNTHESIZING METHOD | ADAR, RNGTT, ATIC | ADORA1 1439/4885SLC29A1 157/4885ADORA3 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.